These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 32243837)

  • 1. KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
    Alam H; Tang M; Maitituoheti M; Dhar SS; Kumar M; Han CY; Ambati CR; Amin SB; Gu B; Chen TY; Lin YH; Chen J; Muller FL; Putluri N; Flores ER; DeMayo FJ; Baseler L; Rai K; Lee MG
    Cancer Cell; 2020 Apr; 37(4):599-617.e7. PubMed ID: 32243837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia/BRCA pathway upon glycolytic inhibition in squamous cell carcinoma.
    Liu W; Cao H; Wang J; Elmusrati A; Han B; Chen W; Zhou P; Li X; Keysar S; Jimeno A; Wang CY
    Nat Commun; 2024 Aug; 15(1):6755. PubMed ID: 39117659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
    Maitituoheti M; Keung EZ; Tang M; Yan L; Alam H; Han G; Singh AK; Raman AT; Terranova C; Sarkar S; Orouji E; Amin SB; Sharma S; Williams M; Samant NS; Dhamdhere M; Zheng N; Shah T; Shah A; Axelrad JB; Anvar NE; Lin YH; Jiang S; Chang EQ; Ingram DR; Wang WL; Lazar A; Lee MG; Muller F; Wang L; Ying H; Rai K
    Cell Rep; 2020 Oct; 33(3):108293. PubMed ID: 33086062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
    Guo C; Chen LH; Huang Y; Chang CC; Wang P; Pirozzi CJ; Qin X; Bao X; Greer PK; McLendon RE; Yan H; Keir ST; Bigner DD; He Y
    Oncotarget; 2013 Nov; 4(11):2144-53. PubMed ID: 24240169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MLL4 Is Required to Maintain Broad H3K4me3 Peaks and Super-Enhancers at Tumor Suppressor Genes.
    Dhar SS; Zhao D; Lin T; Gu B; Pal K; Wu SJ; Alam H; Lv J; Yun K; Gopalakrishnan V; Flores ER; Northcott PA; Rajaram V; Li W; Shilatifard A; Sillitoe RV; Chen K; Lee MG
    Mol Cell; 2018 Jun; 70(5):825-841.e6. PubMed ID: 29861161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USP53 promotes apoptosis and inhibits glycolysis in lung adenocarcinoma through FKBP51-AKT1 signaling.
    Zhao X; Wu X; Wang H; Yu H; Wang J
    Mol Carcinog; 2020 Aug; 59(8):1000-1011. PubMed ID: 32511815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment.
    Zhao Z; Aoi Y; Philips CN; Meghani KA; Gold SR; Yu Y; John LS; Qian J; Zeidner JM; Meeks JJ; Shilatifard A
    Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2310063120. PubMed ID: 38113256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of Function of the Gene Encoding the Histone Methyltransferase KMT2D Leads to Deregulation of Mitochondrial Respiration.
    Pacelli C; Adipietro I; Malerba N; Squeo GM; Piccoli C; Amoresano A; Pinto G; Pucci P; Lee JE; Ge K; Capitanio N; Merla G
    Cells; 2020 Jul; 9(7):. PubMed ID: 32668765
    [No Abstract]   [Full Text] [Related]  

  • 9. KMT2D regulates specific programs in heart development via histone H3 lysine 4 di-methylation.
    Ang SY; Uebersohn A; Spencer CI; Huang Y; Lee JE; Ge K; Bruneau BG
    Development; 2016 Mar; 143(5):810-21. PubMed ID: 26932671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
    Augert A; Zhang Q; Bates B; Cui M; Wang X; Wildey G; Dowlati A; MacPherson D
    J Thorac Oncol; 2017 Apr; 12(4):704-713. PubMed ID: 28007623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc.
    Yao B; Xing M; Zeng X; Zhang M; Zheng Q; Wang Z; Peng B; Qu S; Li L; Jin Y; Li H; Yuan H; Zhao Q; Ma C
    Clin Transl Med; 2024 Jul; 14(7):e1753. PubMed ID: 38967349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells.
    Kim JH; Sharma A; Dhar SS; Lee SH; Gu B; Chan CH; Lin HK; Lee MG
    Cancer Res; 2014 Mar; 74(6):1705-17. PubMed ID: 24491801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone H3 lysine 4 methyltransferase KMT2D.
    Froimchuk E; Jang Y; Ge K
    Gene; 2017 Sep; 627():337-342. PubMed ID: 28669924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The low-complexity domains of the KMT2D protein regulate histone monomethylation transcription to facilitate pancreatic cancer progression.
    Li W; Wu L; Jia H; Lin Z; Zhong R; Li Y; Jiang C; Liu S; Zhou X; Zhang E
    Cell Mol Biol Lett; 2021 Nov; 26(1):45. PubMed ID: 34758724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.
    Zhang C; Chen L; Liu Y; Huang J; Liu A; Xu Y; Shen Y; He H; Xu D
    Theranostics; 2021; 11(8):3676-3693. PubMed ID: 33664855
    [No Abstract]   [Full Text] [Related]  

  • 16. DBC1 is a key positive regulator of enhancer epigenomic writers KMT2D and p300.
    Kim HJ; Moon SJ; Hong S; Won HH; Kim JH
    Nucleic Acids Res; 2022 Aug; 50(14):7873-7888. PubMed ID: 35801925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation.
    Lee JE; Wang C; Xu S; Cho YW; Wang L; Feng X; Baldridge A; Sartorelli V; Zhuang L; Peng W; Ge K
    Elife; 2013 Dec; 2():e01503. PubMed ID: 24368734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53 regulates enhancer-associated H3K4 monomethylation through interactions with the methyltransferase MLL4.
    Rahnamoun H; Hong J; Sun Z; Lee J; Lu H; Lauberth SM
    J Biol Chem; 2018 Aug; 293(34):13234-13246. PubMed ID: 29954944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KMT2C and KMT2D aberrations in breast cancer.
    Tinsley E; Bredin P; Toomey S; Hennessy BT; Furney SJ
    Trends Cancer; 2024 Jun; 10(6):519-530. PubMed ID: 38453563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KMT2D regulates activation, localization, and integrin expression by T-cells.
    Potter SJ; Zhang L; Kotliar M; Wu Y; Schafer C; Stefan K; Boukas L; Qu'd D; Bodamer O; Simpson BN; Barski A; Lindsley AW; Bjornsson HT
    Front Immunol; 2024; 15():1341745. PubMed ID: 38765012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.